These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24310589)

  • 61. Application of freeze-drying technology in manufacturing orally disintegrating films.
    Liew KB; Odeniyi MA; Peh KK
    Pharm Dev Technol; 2016; 21(3):346-53. PubMed ID: 25597618
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The preparation of rapidly disintegrating tablets in the mouth.
    Sugimoto M; Matsubara K; Koida Y; Kobayashi M
    Pharm Dev Technol; 2001 Nov; 6(4):487-93. PubMed ID: 11775950
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel Orally Disintegrating Tablets Produced Using a High-Pressure Carbon Dioxides Process.
    Kobayashi M; Shinozuka D; Kondo H; Sako K; Otake K
    Chem Pharm Bull (Tokyo); 2018; 66(10):932-938. PubMed ID: 30270240
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Experimentally designed lyophilized dry emulsion tablets for enhancing the antihyperlipidemic activity of atorvastatin calcium: Preparation, in-vitro evaluation and in-vivo assessment.
    Salama AH; Basha M; El Awdan S
    Eur J Pharm Sci; 2018 Jan; 112():52-62. PubMed ID: 29117504
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recent patents and trends in orally disintegrating tablets.
    AlHusban FA; El-Shaer AM; Jones RJ; Mohammed AR
    Recent Pat Drug Deliv Formul; 2010 Nov; 4(3):178-97. PubMed ID: 20626334
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management.
    Mennini N; Orlandini S; Furlanetto S; Pasquini B; Mura P
    Curr Drug Deliv; 2018; 15(3):436-445. PubMed ID: 28595529
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reconstitution Time for Highly Concentrated Lyophilized Proteins: Role of Formulation and Protein.
    Kulkarni SS; Patel SM; Bogner RH
    J Pharm Sci; 2020 Oct; 109(10):2975-2985. PubMed ID: 32534031
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Establishment of a Novel Method to Evaluate Water Permeation Rates by Combining the Dynamic Contact Angle and Thermographic Approach: Significance of Disintegration Properties of Orally Disintegrating Tablets].
    Suzuki T; Kurano T; Kanazawa T; Suzuki N
    Yakugaku Zasshi; 2020; 140(8):1071-1080. PubMed ID: 32741865
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Application of general multilevel factorial design with formulation of fast disintegrating tablets containing croscaremellose sodium and Disintequick MCC-25.
    Solaiman A; Suliman AS; Shinde S; Naz S; Elkordy AA
    Int J Pharm; 2016 Mar; 501(1-2):87-95. PubMed ID: 26827922
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets.
    Morott JT; Pimparade M; Park JB; Worley CP; Majumdar S; Lian Z; Pinto E; Bi Y; Durig T; Repka MA
    J Pharm Sci; 2015 Jan; 104(1):124-34. PubMed ID: 25410968
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oxytetracyline tablet formulations: effect of variations in binder concentration and volume on granule and tablet properties.
    Chalmers AA; Elworthy PH
    J Pharm Pharmacol; 1976 Mar; 28(3):228-33. PubMed ID: 6697
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Formulation development and evaluation of fast disintegrating tablets of salbutamol sulphate, cetirizine hydrochloride in combined pharmaceutical dosage form: a new era in novel drug delivery for pediatrics and geriatrics.
    Sharma D; Singh G; Kumar D; Singh M
    J Drug Deliv; 2015; 2015():640529. PubMed ID: 25810924
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Design, Optimization, and Correlation of In Vitro/In Vivo Disintegration of Novel Fast Orally Disintegrating Tablet of High Dose Metformin Hydrochloride Using Moisture Activated Dry Granulation Process and Quality by Design Approach.
    H Aodah A; H Fayed M; Alalaiwe A; B Alsulays B; F Aldawsari M; Khafagy ES
    Pharmaceutics; 2020 Jun; 12(7):. PubMed ID: 32605039
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Microstructure of Tablet-Pharmaceutical Significance, Assessment, and Engineering.
    Sun CC
    Pharm Res; 2017 May; 34(5):918-928. PubMed ID: 27380192
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets.
    Wagner-Hattler L; Wyss K; Schoelkopf J; Huwyler J; Puchkov M
    Int J Pharm; 2017 Dec; 534(1-2):50-59. PubMed ID: 28987455
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Studies on metronidazole tablet formulations.
    Itiola OA; Pilpel N
    J Pharm Pharmacol; 1986 Feb; 38(2):81-6. PubMed ID: 2870167
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Formulation and evaluation of a novel matrix-type orally disintegrating Ibuprofen tablet.
    Tayebi H; Mortazavi SA
    Iran J Pharm Res; 2011; 10(3):469-79. PubMed ID: 24250378
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fabrication and optimization of fast disintegrating tablets employing interpolymeric chitosan-alginate complex and chitin as novel superdisintegrants.
    Goel H; Tiwary AK; Rana V
    Acta Pol Pharm; 2011; 68(4):571-83. PubMed ID: 21796940
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression.
    Tafere C; Yilma Z; Abrha S; Yehualaw A
    PLoS One; 2021; 16(3):e0246648. PubMed ID: 33725014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.